Qianqian Liu
Biostatistician on one of the first randomised pilot trials of rapamycin's safety in older adults
Department of Population Health Sciences · UT Health San Antonio, USA
Qianqian Liu contributed biostatistical work to the 2018 Kraig et al. paper — one of the earliest placebo-controlled human pilot trials testing whether low-dose rapamycin (1 mg/day) is safe and tolerable in healthy older adults (70-95 years old), run out of UT Health San Antonio's Barshop Institute for Longevity and Aging Studies.
The trial found short-term rapamycin was generally well tolerated, with only mild hematologic changes and no worsening of glucose metabolism, cognition, or physical performance — a result that helped pave the way for the larger human longevity trials of mTOR inhibition that followed.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2018 | H | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort KRA2018 Contributed biostatistical work to the UT Health San Antonio pilot trial showing short-term low-dose rapamycin is safe and tolerable in healthy older adults, an early human proof-of-concept for mTOR-inhibition longevity research. |